Novartis acquires kidney disease innovator Chinook Therapeutics
Swiss pharmaceutical giant Novartis has wrapped up the previously announced $3.5 billion acquisition of Seattle-based biopharmaceutical firm Chinook Therapeutics, Inc. This deal propels Novartis deeper ... Read More
Novartis to expand renal portfolio with Chinook Therapeutics acquisition
Novartis has announced its agreement to acquire Chinook Therapeutics, a clinical stage biopharmaceutical company based in Seattle, Washington in a deal worth up to around ... Read More
Novartis gets Leqvio FDA approval for reducing bad cholesterol levels
Novartis has secured approval from the US Food and Drug Administration (FDA) for its small interfering RNA (siRNA) therapy Leqvio (inclisiran) for its use in ... Read More
Novartis to acquire AveXis for $8.7bn to expand gene therapy and neuroscience portfolio
Novartis, a Swiss pharmaceutical giant, has confirmed a substantial acquisition of AveXis, a US-based gene therapy company, for a total of $8.7 billion. This strategic ... Read More
GlaxoSmithKline to acquire full ownership of consumer healthcare venture from Novartis for $13bn
In a major strategic shift, GlaxoSmithKline (GSK) has finalized an agreement to acquire Novartis' 36.5% stake in their consumer healthcare joint venture for $13 billion. ... Read More